NASDAQ:AUXL - Auxilium Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$36.47
Today's RangeN/A
52-Week Range$17.10 - $37.92
VolumeN/A
Average Volume1.32 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men's healthcare. The company's products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.

Receive AUXL News and Ratings via Email

Sign-up to receive the latest news and ratings for AUXL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
Current SymbolNASDAQ:AUXL
CUSIP05334D10
Phone+1-484-3215900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Auxilium Pharmaceuticals (NASDAQ:AUXL) Frequently Asked Questions

What is Auxilium Pharmaceuticals' stock symbol?

Auxilium Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUXL."

How were Auxilium Pharmaceuticals' earnings last quarter?

Auxilium Pharmaceuticals Inc (NASDAQ:AUXL) announced its earnings results on Thursday, October, 30th. The biopharmaceutical company reported $0.27 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.30. The biopharmaceutical company earned $109.60 million during the quarter, compared to analysts' expectations of $101.02 million. Auxilium Pharmaceuticals's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.17 earnings per share. View Auxilium Pharmaceuticals' Earnings History.

Has Auxilium Pharmaceuticals been receiving favorable news coverage?

Headlines about AUXL stock have been trending neutral on Tuesday, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Auxilium Pharmaceuticals earned a daily sentiment score of 0.4 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the immediate future.

How do I buy shares of Auxilium Pharmaceuticals?

Shares of AUXL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Auxilium Pharmaceuticals' official website?

The official website for Auxilium Pharmaceuticals is http://www.auxilium.com.

How can I contact Auxilium Pharmaceuticals?

Auxilium Pharmaceuticals' mailing address is 640 Lee Rd, CHESTERBROOK, PA 19087-5636, United States. The biopharmaceutical company can be reached via phone at +1-484-3215900.


MarketBeat Community Rating for Auxilium Pharmaceuticals (NASDAQ AUXL)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  255 (Vote Outperform)
Underperform Votes:  188 (Vote Underperform)
Total Votes:  443
MarketBeat's community ratings are surveys of what our community members think about Auxilium Pharmaceuticals and other stocks. Vote "Outperform" if you believe AUXL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUXL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/19/2019 by MarketBeat.com Staff

Featured Article: What is a capital gain?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel